PriceSensitive

Optiscan Imaging (ASX:OIL) releases further partnership information on ASX request

ASX News, Health Care
ASX:OIL      MCAP $70.16M
28 June 2022 13:43 (AEST)

Source: Optiscan

Optiscan Imaging (OIL) has released further information on its new partnership deal at the request of the ASX.

The company announced yesterday it has penned a distributor partnership with Sinsi Technology for the ViewnVivo device. The deal will see the device released to the greater China market, including Hong Kong and Macau.

Sinsi Technology has over 20 years’ experience representing a range of international organisations in China in the biotechnology and life science sectors. The company is said to have an established service network across the country, which further enhances its ability to represent Optiscan and its ViewnVivo device to the market.

ViewnVivo is a miniaturised fluorescence endomicroscope platform that allows real-time in vivo imaging of living tissue.

The company today advised the agreement has an initial term of two years, with the ability to extend for a further 12 months.

The contract includes minimum purchase targets for the distributor. If these targets are met, the revenue is believed to become material.

Either party holds the option to terminate the agreement in the event of any breach of the contract’s terms.

Optiscan last traded in the grey at 9.8 cents at 1:15 pm AEST.  

Related News